Filing Details
- Accession Number:
- 0000899243-18-018143
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-06-26 16:30:49
- Reporting Period:
- 2018-06-22
- Accepted Time:
- 2018-06-26 16:30:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1731831 | Eidos Therapeutics Inc. | EIDX | Pharmaceutical Preparations (2834) | 463733671 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1743881 | Bridgebio Pharma Llc | 421 Kipling St Palo Alto CA 94301 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-06-22 | 18,826,417 | $0.00 | 18,826,417 | No | 4 | C | Direct | |
| Common Stock | Disposition | 2018-06-22 | 211,762 | $17.00 | 18,614,655 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2018-06-22 | 1,000,000 | $17.00 | 19,614,655 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | F | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Series B Preferred Stock | Warrants | Disposition | 2018-06-22 | 332,262 | $0.00 | 332,262 | $10.83 |
| Common Stock | Series B Preferred Stock | Acquisiton | 2018-06-22 | 332,262 | $0.00 | 397,385 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2018-06-22 | 2,909,029 | $0.00 | 3,479,198 | $0.00 |
| Common Stock | Series Seed Preferred Stock | Disposition | 2018-06-22 | 12,832,123 | $0.00 | 15,347,219 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | X | Direct | ||
| 2,909,029 | No | 4 | X | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.
- Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.
Billionaire Hedge Funds
